Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTO: Cilengitide + Cetuximab + Chemo in Advanced NSCLC
NCT00842712Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of cilengitide in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Merck KGaA. Primary endpoints: Maximum Tolerated Dose and Progression-Free Survival. Started Feb 2009; status: completed.
02
Drugs
cilengitide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00842712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842712.